The House of Representatives, on Thursday, voted 230-192 to pass Speaker Nancy Pelosi’s, D-California, HR 3, the Elijah E. Cummings Lower Drug Costs Now Act, although the White House has already said it will veto the measure, assuming it is ever brought to the Senate floor and passes.
The House of Representatives, on Thursday, voted 230-192 to pass Speaker Nancy Pelosi’s, D-California, HR 3, the Elijah E. Cummings Lower Drug Costs Now Act, although the White House has already said it will veto the measure, assuming it is ever brought to the Senate floor and passes.
Legislators debated for hours Wednesday night and Thursday morning on what has the potential to be a complete overhaul in US prescription drug pricing.
For the first time, HHS would have the ability to allow Medicare to negotiate certain drug prices and seek rebates from drug makers if their prices soar above inflation.
The secretary of HHS would be authorized annually to negotiate prices for up to 250 of the most costly drugs that lack a generic or biosimilar competitor, including both Part D and Part B. Insulin would have been included as well, and Wednesday night, some Democratic representatives talked about the impact insulin pricing has had on their constituents.
On the other side of the aisle, Republican lawmakers advocated instead for HR 19, the Lower Costs, More Cures Act, and said that HR 3 would reduce pharmaceutical and biotech innovation, even possible cures.
The lawmakers were referring to an October Congressional Budget Office preliminary estimate that if HR 3 becomes law, between 8 and 15 fewer drugs would come to market over 10 years.
In a post earlier this month, however, PolitiFact, a nonprofit, nonpartisan news organization, pointed out that the FDA approves about 30 new drugs, on average, annually—or 300 new drugs over 10 years. Over time, the loss of new therapeutics would be perhaps 5%, if there were 15 fewer drugs out of 300 projected approvals. In addition, there has been no analysis about the clinical value of these potential future drugs that might not ever come to market.
HR 3 was supported by organizations like the AARP.
“High drug prices disproportionately hurt older Americans, who take an average of four to five prescription medications each month. The average annual price of a single specialty drug now costs $79,000. Medicare beneficiaries have modest median annual incomes of just over $26,000. Medications cannot help you if you cannot afford them,” said Nancy LeaMonde, AARP’s executive vice president and chief advocacy and engagement officer, in a statement Wednesday.
HR 3 will assign penalties to drug companies that refuse to negotiate with HHS on pricing. It would also require drug makers to pay rebates to Medicare if they hike their prices beyond the increase in inflation, and cap what seniors pay out of pocket for their medications to $2000 a year.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.